Danny Luan receives the 2019 ASH HONORS award
Asaf Zviran receives the 2018 NYGC Innovation Award for his liquid biopsy work
Nathan Omans Selected as a NYSTEM Stem Cell Biology Scholar
Dan Landau receives the 2017 American Society of Hematology Joanne Levy, MD, Memorial Award for Outstanding Achievement
Franco Izzo awarded the American Society of Hematology Outstanding Achievement Abstract Award for submitting the top-scoring abstract of the 2017 annual meeting
Dan Landau selected for HemOnc Today’s Next Gen Innovators
Columbia University Physical Sciences in Oncology Center pilot grant awarded in collaboration with the Rabadan lab (CU) for novel multi-omics single cell technology development
This award will fund the development of novel epigenetic single-cell and editing technology
The Landau lab receives prestigious Broad Next 10 Catalytic Steps funding
The Broad Institute will provide 500,000$ in funding over the next year to develop "Modeling Cancer Diversity and Evolution for Precision Combination Cancer Therapeutics". This ambitious project will be carried out jointly with Cory Johannessen at the Broad Institute, to identify novel ways to overcome lung cancer evolution and resistance to therapy.
The Kimmel Scholar award will fund a project titled: "Knowledge infrastructure for data-driven combination leukemia therapy engineering."
Dan Landau receives the 2016 Young Physician-Scientist Award by the American Society of Clinical Investigation
To be presented in April at the AAP-ASPA-ASCI joint annual meeting in Chicago.
This award will fund the development of dynamic therapeutic optimization based on liquid biopsy technology
This award will fund the development of new liquid biopsy technology for early cancer detection
Quantitative Clonal Dynamics Define Mechanisms of CLL Evolution in Response to Combination Chemotherapy – selected for Best of ASH
Dense temporal sampling of leukemia samples from patients treated with chemoimmunotherapy enabled the study of evolutionary kinetics directly in patients. These data describe innovative methodologies to measure clone-specific growth rates with differing therapeutic contexts. The project lays the foundations for algorithmycally-driven therapy based on real-time monitoring of clonal growth. The results were presented at the annual meeting of the American Society of Hematology (ASH) and selected for the Best of ASH presentation.